Mark Pollack to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Mark Pollack has written about Dose-Response Relationship, Drug.
Connection Strength
0.716
-
Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: Further evaluation. Behav Res Ther. 2010 Aug; 48(8):720-7.
Score: 0.086
-
Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol. 2008 Jun; 28(3):308-16.
Score: 0.076
-
Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl). 2008 May; 197(4):675-81.
Score: 0.074
-
A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl). 2007 Oct; 194(2):233-42.
Score: 0.071
-
A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety. 2007; 24(1):1-14.
Score: 0.069
-
Benzodiazepines in clinical practice: consideration of their long-term use and alternative agents. J Clin Psychiatry. 2005; 66 Suppl 2:21-7.
Score: 0.060
-
Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl). 2005 Jan; 177(3):280-8.
Score: 0.058
-
Do antidepressants selectively suppress spontaneous (unexpected) panic attacks? A replication. J Clin Psychopharmacol. 2000 Dec; 20(6):622-7.
Score: 0.045
-
Adjunctive yohimbine for treatment in refractory depression. Biol Psychiatry. 1993 Feb 01; 33(3):220-1.
Score: 0.026
-
Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. J Clin Psychiatry. 2012 Mar; 73(3):353-7.
Score: 0.024
-
Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr. 2008 Jun; 13(6):522-7.
Score: 0.019
-
Propranolol and depression revisited: three cases and a review. J Nerv Ment Dis. 1985 Feb; 173(2):118-9.
Score: 0.015
-
Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder. Psychol Med. 2003 Apr; 33(3):511-8.
Score: 0.013
-
Pseudomonas aeruginosa exotoxin A inhibits proliferation of human bone marrow progenitor cells in vitro. Infect Immun. 1982 Oct; 38(1):206-11.
Score: 0.013
-
Strategies for treatment of SSRI-associated sexual dysfunction: a survey of an academic psychopharmacology practice. Harv Rev Psychiatry. 2002 Mar-Apr; 10(2):109-14.
Score: 0.012
-
Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand. 2001 Oct; 104(4):289-98.
Score: 0.012
-
Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. Br J Psychiatry. 1999 Mar; 174:213-8.
Score: 0.010
-
Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry. 1998 Nov; 155(11):1570-7.
Score: 0.010
-
Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol. 1997 Aug; 17(4):247-54.
Score: 0.009
-
The relationship of alprazolam and clonazepam dose to steady-state concentration in plasma. J Clin Psychopharmacol. 1994 Aug; 14(4):274-6.
Score: 0.007
-
The antidepressant potential of oral S-adenosyl-l-methionine. Acta Psychiatr Scand. 1990 May; 81(5):432-6.
Score: 0.005
-
A prospective double-blind study of side effects associated with the administration of amantadine for influenza A virus prophylaxis. J Infect Dis. 1980 May; 141(5):543-7.
Score: 0.003